Skip to content

Revolution Medicines

US · RVMD #499 by market cap Listed 2020
200.87 +1.00 +0.50%
Live - 5344 symbols - heartbeat 227s ago · 2026-10-08 08:07
Pre-market 200.44 -0.21%
After-hours 199.81 -0.53%
Overnight 199.95 -0.46%
Market cap
43.05B
P/B
16.52
EPS
-5.95
Reader sentiment Are you bullish or bearish on RVMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.4 percentage points.

Institutional ownership

Held by institutions
100.56% -1.39pp
Institutions
813 +1
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund52.90%
Hedge Fund32.38%
VC/PE Fund8.50%
Public Company2.41%
Individual/Insider2.22%
Private Company2.01%
Sovereign Wealth Fund1.11%
Government Pension Fund0.83%
Family Office/Trust0.23%

Top holders as of 2026-06-30

BlackRock 6.39% · 13.70M sh
Farallon Capital Management, L.L.C. 6.32% · 13.55M sh
FMR 5.60% · 12.00M sh
Baker Bros. Advisors LP 5.34% · 11.44M sh
Janus Henderson Group plc 5.01% · 10.74M sh
Darwin Global Management Limited 4.96% · 10.63M sh
Vanguard Capital Management, LLC 4.84% · 10.38M sh
Vanguard Portfolio Management, LLC 3.87% · 8.29M sh
Nextech Invest Ltd. 3.55% · 7.60M sh
Paradigm Biocapital Advisors LP 2.97% · 6.36M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 15 buys · 35 sells

NameRoleStake
Alexis Borisy Lead Independent Director 1.09%
Mark Goldsmith Chief Executive Officer 0.37%
Thilo Schroeder Independent Director 0.35%
Stephen Kelsey President of Research & Development 0.10%
Margaret Horn Chief Operating Officer 0.07%
Sandra Horning Independent Director 0.04%
Jack Anders Chief Financial Officer 0.04%
Xiaolin Wang Executive Vice President of Clinical Development 0.03%
Alan Bart Sandler Chief Development Officer 0.02%
Elizabeth Anderson Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-28 Alan Bart Sandler Chief Development Officer Automatic Disposition -309 $203.91–204.72
2026-09-28 Alan Bart Sandler Chief Development Officer Derivative Exercise and Sale -6,000 $58.84–203.91
2026-09-24 Anthony Mancini Chief Global Commercialization Officer Derivative Exercise and Sale -3,121 $33.62–200.54
2026-09-24 Jeffrey Cislini Senior Vice President Automatic Disposition -765 $207.32
2026-09-23 Anthony Mancini Chief Global Commercialization Officer Automatic Disposition -587 $200.00
2026-09-21 Elizabeth Anderson Independent Director Automatic Disposition -5,073 $192.54–195.15
2026-09-21 Elizabeth Anderson Independent Director Derivative Exercise and Sale -5,070 $1.12–192.54
2026-09-17 Anthony Mancini Chief Global Commercialization Officer Automatic Disposition -1,764 $196.94
2026-09-15 Mark Goldsmith Chief Executive Officer Open Market Disposition -13,988 $195.01–199.30
2026-09-15 Margaret Horn Chief Operating Officer Automatic Disposition -4,967 $195.01–199.30
2026-09-15 Stephen Kelsey President of Research & Development Open Market Disposition -5,569 $195.01–199.30
2026-09-15 Alan Bart Sandler Chief Development Officer Automatic Disposition -341 $194.96–199.30
2026-09-15 Anthony Mancini Chief Global Commercialization Officer Open Market Disposition -1,774 $195.05–199.30
2026-09-15 Jack Anders Chief Financial Officer Open Market Disposition -4,053 $195.00–199.30
2026-09-15 Jeffrey Cislini Senior Vice President Open Market Disposition -3,366 $195.01–199.30
2026-09-14 Mark Goldsmith Chief Executive Officer Intent to Sell (Form 144) -13,603 $203.77
2026-09-14 Margaret Horn Chief Operating Officer Intent to Sell (Form 144) -4,830 $203.77
2026-09-14 Stephen Kelsey President of Research & Development Intent to Sell (Form 144) -5,415 $203.77
2026-09-14 Alan Bart Sandler Chief Development Officer Intent to Sell (Form 144) -331 $203.77
2026-09-14 Anthony Mancini Chief Global Commercialization Officer Intent to Sell (Form 144) -2,377 $203.77

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 08:07:59 · For reference only, not investment advice and not tailored to your situation.